Atara Biotherapeutics (AT20) Stock Statistics & Valuation Metrics
Total Valuation
Atara Biotherapeutics has a market cap or net worth of EUR 71.99M. The enterprise value is EUR 214.12M.
- Market Cap
- EUR 71.99M
- Enterprise Value
- EUR 214.12M
Share Statistics
Atara Biotherapeutics has 10,037,710 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,037,710
- Owned by Insiders
- 51.23%
- Owned by Institutions
- 7.81%
Financial Efficiency
Atara Biotherapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is 222.66%.
- Return on Equity (ROE)
- -0.85
- Return on Assets (ROA)
- 1.62
- Return on Invested Capital (ROIC)
- 222.66%
- Return on Capital Employed (ROCE)
- 6.75
- Revenue Per Employee
- 12.08M
- Profits Per Employee
- 3.27M
- Employee Count
- 10
- Asset Turnover
- 5.97
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Atara Biotherapeutics is -6.79. Atara Biotherapeutics’s PEG ratio is 0.05.
- PE Ratio
- -6.79
- PS Ratio
- 12.98
- PB Ratio
- -3.25
- Price to FCF
- -3.67
- Price to Operating Cash Flow
- -5.50
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of 120.77M and earned 32.69M in profits. Earnings per share was 2.61.
- Revenue
- 120.77M
- Gross Profit
- 99.56M
- Operating Income
- 35.86M
- Pretax Income
- 32.72M
- Net Income
- 32.69M
- EBITDA
- 38.63M
- Earnings Per Share (EPS)
- 2.61
Cash Flow
In the last 12 months, operating cash flow was -21.89M and capital expenditures 0, giving a free cash flow of -21.89M billion.
- Operating Cash Flow
- -21.89M
- Free Cash Flow
- -21.89M
- Free Cash Flow per Share
- -1.46
Dividends & Yields
Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.54%
- Earnings Yield
- -13.00%
Stock Price Statistics
- Beta
- 1.00
- 52-Week Price Change
- -38.66%
- 50-Day Moving Average
- 7.91
- 200-Day Moving Average
- 6.62
- Relative Strength Index (RSI)
- 43.84
- Average Volume (3m)
- 200
Important Dates
Atara Biotherapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Atara Biotherapeutics as a current ratio of 0.82, with Debt / Equity ratio of -137.13%
- Current Ratio
- 0.82
- Quick Ratio
- 0.82
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- 1.15
- Interest Coverage Ratio
- 9.46
Taxes
In the past 12 months, Atara Biotherapeutics has paid 31.00K in taxes.
- Income Tax
- 31.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Atara Biotherapeutics EV to EBITDA ratio is -6.74, with an EV/FCF ratio of -4.22.
- EV to Sales
- 14.91
- EV to EBITDA
- -6.74
- EV to Free Cash Flow
- -4.22
- EV to Operating Cash Flow
- -4.22
Balance Sheet
Atara Biotherapeutics has EUR 9.87M in cash and marketable securities with EUR 9.88M in debt, giving a net cash position of -EUR 6,000.00 billion.
- Cash & Marketable Securities
- EUR 9.87M
- Total Debt
- EUR 9.88M
- Net Cash
- -EUR 6,000.00
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- -EUR 2.46
Margins
Gross margin is 91.38%, with operating margin of -229.67%, and net profit margin of -269.42%.
- Gross Margin
- 91.38%
- Operating Margin
- -229.67%
- Pretax Margin
- -268.95%
- Net Profit Margin
- -269.42%
- EBITDA Margin
- -221.29%
- EBIT Margin
- -223.36%
Analyst Forecast
The average price target for Atara Biotherapeutics is EUR 13.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 13.83
- Price Target Upside
- 89.48% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -96.98%
- EPS Growth Forecast
- -367.52%
Scores
- Smart Score
- 8
- AI Score
- ―
